MCT8 mutation analysis and identification of the first female with Allan-Herndon-Dudley syndrome due to loss of MCT8 expression.

Eur J Hum Genet 2008 Sep 9;16(9):1029-37. Epub 2008 Apr 9.

Department of Clinical Genetics, University Hospital azM Maastricht, Maastricht, The Netherlands.

Mutations in the thyroid monocarboxylate transporter 8 gene (MCT8/SLC16A2) have been reported to result in X-linked mental retardation (XLMR) in patients with clinical features of the Allan-Herndon-Dudley syndrome (AHDS). We performed MCT8 mutation analysis including 13 XLMR families with LOD scores >2.0, 401 male MR sibships and 47 sporadic male patients with AHDS-like clinical features. One nonsense mutation (c.629insA) and two missense changes (c.1A>T and c.1673G>A) were identified. Consistent with previous reports on MCT8 missense changes, the patient with c.1673G>A showed elevated serum T3 level. The c.1A>T change in another patient affects a putative translation start codon, but the same change was present in his healthy brother. In addition normal serum T3 levels were present, suggesting that the c.1A>T (NM_006517) variation is not responsible for the MR phenotype but indicates that MCT8 translation likely starts with a methionine at position p.75. Moreover, we characterized a de novo translocation t(X;9)(q13.2;p24) in a female patient with full blown AHDS clinical features including elevated serum T3 levels. The MCT8 gene was disrupted at the X-breakpoint. A complete loss of MCT8 expression was observed in a fibroblast cell-line derived from this patient because of unfavorable nonrandom X-inactivation. Taken together, these data indicate that MCT8 mutations are not common in non-AHDS MR patients yet they support that elevated serum T3 levels can be indicative for AHDS and that AHDS clinical features can be present in female MCT8 mutation carriers whenever there is unfavorable nonrandom X-inactivation.

Download full-text PDF

Source Listing
September 2008
28 Reads

Publication Analysis

Top Keywords

clinical features
elevated serum
serum levels
mct8 mutation
mct8 expression
ahds clinical
nonrandom x-inactivation
unfavorable nonrandom
allan-herndon-dudley syndrome
loss mct8
missense changes
mutation analysis
translation starts
levels suggesting
starts methionine
normal serum
healthy brother
brother addition
addition normal


(Supplied by CrossRef)

EC Friesema et al.
Lancet 2004

K Brockmann et al.
J Neurol 2005

KR Holden et al.
J Child Neurol 2005

CE Schwartz et al.
Am J Hum Genet 2005

CM Maranduba et al.
J Med Genet 2006

V Herzovich et al.
Horm Res 2007

CE Schwartz et al.
Best Pract Res Clin Endocrinol Metab 2007

EC Friesema et al.
Nat Clin Pract Endocrinol Metab 2006

AP de Brouwer et al.
Hum Mutat 2007

LR Jensen et al.
Eur J Hum Genet 2007

RC Allen et al.
Am J Hum Genet 1992

Similar Publications